use
adenoviru
ad
vaccin
vector
hinder
preexist
immun
human
ad
human
popul
order
overcom
limit
uncommon
altern
ad
serotyp
need
util
studi
delet
recombin
ad
base
chimpanze
serotyp
engin
express
human
carcinoembryon
antigen
cea
protein
rat
neu
extracellulartransmembran
domain
ecdtm
vector
test
cea
transgen
ceatg
balbneut
mice
show
immunolog
toler
antigen
capabl
induc
immun
respons
compar
serotypebas
vector
thu
break
toler
tumor
associ
antigen
taa
achiev
antitumor
effect
import
overcom
preexist
immun
work
conjunct
dna
electropor
dnaep
ad
vaccin
base
common
human
serotyp
adenovirus
ad
compris
larg
famili
doublestrand
dna
virus
found
amphibian
avian
mammal
nonenvelop
icosahedr
capsid
structur
ad
vector
develop
gene
therapi
purpos
aim
treat
inherit
acquir
diseas
howev
high
immunogen
ad
recombin
exclud
success
use
sustain
gene
therapi
led
develop
vaccin
carrier
ad
vaccin
shown
induc
highest
band
tcell
respons
experiment
anim
includ
rodent
canin
primat
test
human
clinic
trial
antigen
ad
vector
evalu
addit
clinic
trial
use
dna
vaccin
prime
regimen
follow
ad
vector
booster
immun
ad
vector
use
treatment
mani
diseas
predominantli
deriv
human
serotyp
although
sever
issu
still
hamper
gene
deliveri
system
includ
inabl
transduc
certain
target
cell
popul
acut
ad
mediat
toxic
vivo
importantli
high
preval
vector
neutral
antibodi
vna
within
human
popul
decreas
gene
transfer
effici
blunt
vaccin
potenc
fact
subgroup
c
includ
adenovir
infect
endem
human
popul
consequ
major
human
seroconvert
within
first
year
life
result
natur
infect
unit
state
depend
age
studi
popul
sensit
assay
human
carri
readili
detect
vna
viru
seropreval
rate
viru
markedli
higher
human
popul
develop
countri
anim
model
includ
nonhuman
primat
nhp
vna
gener
upon
preexposur
viru
shown
previous
strongli
impair
band
tcell
respons
transgen
product
vaccin
base
ad
serotyp
similar
impair
observ
human
volunt
clinic
trial
vaccin
order
overcom
problem
differ
strategi
pursu
includ
immunosuppress
artifici
envelop
lipid
bilay
use
differ
human
ad
serotyp
retarget
human
vector
mask
adenovir
fiber
knob
ablat
bind
coxsackieviru
adenoviru
receptor
car
target
specif
cell
receptor
genet
modif
fiber
vector
encapsul
microparticl
vector
base
human
nonsubgroup
c
adenoviru
previous
report
among
propos
altern
vaccin
deliveri
low
seropreval
comparison
vector
mice
nonhuman
primat
show
lower
immunolog
potenc
latter
vector
similarli
two
vector
base
rare
serotyp
induc
lower
cmi
nonhuman
primat
addit
use
nonhuman
ad
vector
elud
immun
propos
review
sever
nonhuman
ad
natur
nonpathogen
human
well
character
unlik
human
ad
expect
immun
nonhuman
adenovirus
preval
human
popul
shown
preexist
humor
immun
human
crossneutr
ovin
chimpanze
canin
porcin
ad
strategi
particularli
relev
use
ad
vector
cancer
vaccin
fact
one
major
obstacl
achiev
tumorspecif
immun
respons
overcom
central
andor
peripher
cell
toler
taa
induc
ctl
could
effect
erad
dissemin
tumor
metastas
subsequ
maintain
long
last
immunolog
memori
prevent
tumor
recurr
ad
shown
efficaci
vaccin
vector
abl
break
immun
toler
target
antigen
human
taa
transgen
mice
well
nonhuman
primat
increasingli
combin
ad
vector
heterolog
modal
immun
vivo
electropor
plasmid
dna
dnaep
induc
superior
immun
respons
compar
singl
modal
vaccin
studi
describ
use
delet
recombin
ad
vector
obtain
novel
chimpanze
adenoviru
type
belong
subgroup
c
adenovirus
colloca
et
al
prepar
develop
cancer
vaccin
direct
two
model
taa
carcinoembryon
antigen
cea
recogn
optim
target
therapeut
intervent
cea
oncofet
membran
antigen
member
immunoglobulin
gene
superfamili
express
normal
gastrointestin
tissu
overexpress
high
percentag
human
colon
pancreat
breast
lung
adenocarcinoma
oncoprotein
tyrosin
kinas
receptor
overexpress
sever
human
tumor
associ
poor
prognosi
show
vaccin
abl
induc
immun
respons
compar
serotypebas
vector
break
toler
tumor
antigen
overcom
preexist
immun
achiev
antitumor
effect
find
may
signific
impact
develop
adbas
cancer
vaccin
isol
expans
clone
describ
elsewher
colloca
et
al
prepar
briefli
isol
chimpanze
stool
specimen
expand
cell
belong
subgroup
c
ad
viral
genom
bp
homolog
region
bp
low
seropreval
human
sera
titer
respect
capabl
insert
bp
delet
region
colloca
et
al
prepar
plasmid
carri
cea
codon
optim
cdna
previous
describ
gener
describ
elsewher
vector
shuttl
plasmid
contain
codon
optim
human
cea
rat
neu
ecdtm
cdna
driven
hcmv
promot
gener
express
cassett
insert
homolog
recombin
backbon
delet
colloca
et
al
prepar
briefli
cea
rat
neu
ecdtm
express
cassett
excis
polymrkceaopt
polymrkrat
neu
ecdtm
sspiasci
recombin
snabi
linear
replac
egfp
express
cassett
homolog
hcmv
bgh
polya
use
e
coli
cell
result
plasmid
ratneuecdtm
cut
pmei
releas
adenoviru
itr
transfect
cell
human
retinoblastoma
cell
line
provid
viru
virus
expand
serial
passag
cell
purifi
cscl
gradient
centrifug
viral
particl
concentr
determin
spectrophotometri
vitro
vivo
cea
transgen
express
test
elisa
direct
elisa
cea
kit
dbcdiagnost
biochem
canada
inc
rat
neu
ecdtm
express
verifi
fac
amount
transduc
particl
prepar
determin
limit
dilut
cell
lyophil
peptid
purchas
biosynthesi
lewisvil
tx
resuspend
dmso
mgml
pool
cea
peptid
aa
overlap
residu
assembl
previous
describ
particularli
studi
util
cea
pool
peptid
mgml
dmso
encompass
protein
residu
peptid
pool
store
c
mice
transgen
human
cea
ceatg
b
kindli
provid
dr
primu
vanderbilt
univers
femal
balbc
mice
transgen
transform
neut
oncogen
neut
neut
transcript
control
mmtv
promot
transgen
neg
neut
neut
bred
specif
pathogenfre
condit
charl
river
breed
laboratori
calco
itali
kindli
provid
dr
g
forni
univers
torino
itali
experi
mice
anaesthes
isofluran
schere
plough
new
augusta
usa
immun
inject
indic
vp
vector
quadricep
muscl
ceatg
mice
vaccin
dna
inject
total
amount
g
plasmid
dna
one
quadricep
muscl
g
l
physiolog
solut
follow
electropor
ep
previous
describ
end
treatment
period
necropsi
mice
euthan
compress
co
ga
cylind
indic
american
veterinari
medic
associ
avma
panel
euthanasia
accord
guidelin
describ
experi
conduct
accord
eu
direct
protect
anim
use
experiment
scientif
purpos
ratifi
italian
legisl
dl
februari
sera
antibodi
titrat
obtain
retroorbit
bleed
elisa
assay
perform
use
highli
purifi
cea
protein
ratneuecdhfc
previous
describ
anticea
antirat
titer
calcul
plot
serum
dilut
vs
optic
densiti
valu
michaelismenten
curv
fit
data
use
kaleidagraph
synergi
softwar
detect
peripher
immun
respons
measur
previous
describ
briefli
pbmc
resuspend
ml
rpmi
fc
incub
c
h
pool
cea
peptid
rat
neu
tyvpanasl
identifi
previou
studi
gml
final
concentr
peptid
brefeldin
gml
bd
pharmingen
staphylococcu
enterotoxin
b
seb
gml
dmso
use
posit
background
control
cell
wash
stain
surfac
antibodi
wash
cell
fix
permeabil
incub
antibodi
bd
pharmingen
fix
formaldehyd
pb
analyz
facscalibur
flow
cytomet
use
cellquest
softwar
becton
dickinson
mice
receiv
one
two
inject
vector
qbiogenemontr
hereaft
refer
week
later
neutral
antibodi
titer
vs
determin
previous
describ
briefli
viral
particl
express
secret
alkalin
phosphatas
dilut
l
complet
cell
medium
ad
equal
volum
mous
serum
dilut
complet
medium
serum
sampl
test
variou
dilut
sampl
preincub
h
c
ad
cell
seed
well
cellswel
inoculum
remov
cell
refe
fresh
medium
h
later
l
medium
remov
seap
activ
measur
chemiluminesc
assay
phosphalight
system
tm
appli
biosystem
bedford
accord
manufactur
instruct
neutral
titer
defin
dilut
serum
give
reduct
seap
activ
observ
posit
control
viru
alon
student
ttest
logrank
test
perform
indic
p
valu
consid
signific
delet
replicationdefect
vector
contain
codon
optim
cea
sequenc
rat
neu
ecdtm
cdna
construct
homolog
recombin
shown
fig
transgen
clone
cassett
driven
human
cmv
promot
hcmv
bovin
growth
hormon
bgh
polyadenyl
signal
end
vector
rescu
expand
cell
vppfu
ratio
paramet
determin
rel
infect
level
differ
ad
virus
prepar
similar
prepar
verifi
capabl
infect
human
cell
express
antigen
interest
hela
cell
infect
differ
ratio
vp
cell
cea
gpianchor
protein
normal
shed
biolog
fluid
reason
easili
detect
fortyeight
hour
later
supernat
infect
cell
collect
cea
protein
quantifi
elisa
shown
fig
abl
infect
cell
protein
secret
level
compar
infect
cell
next
assess
infect
vector
cea
express
vivo
group
ceatg
inject
intramuscularli
three
dose
vpmous
either
two
adenovir
vector
three
day
later
cea
express
measur
serum
found
level
secret
protein
roughli
lower
vector
fig
ceatg
mice
immun
either
vp
vector
mock
inject
thirti
day
later
mice
boost
indic
vector
week
later
pbmc
analyz
ceaspecif
respons
intracellular
stain
white
circl
indic
immun
respons
measur
per
singl
anim
gray
dot
repres
group
geometr
mean
mice
respons
dash
line
consid
respond
student
ttest
p
vs
group
assess
whether
capabl
break
immunolog
toler
cea
ceatg
mice
measur
kinet
immun
respons
pbmc
analyz
differ
time
point
intracellular
stain
ic
frequenc
ceaspecif
produc
cell
week
singl
treatment
mice
vp
either
vaccin
vector
abl
elicit
signific
immun
respons
reach
peak
level
day
postinject
fig
decreas
basal
level
day
treatment
appar
slower
kinet
observ
vector
better
character
immunogen
potenti
respect
immun
ceatg
mice
escal
dose
viru
one
month
inject
elicit
higher
respons
especi
lower
dose
vp
fig
measur
effect
heterolog
vs
homolog
adbas
vaccin
ceatg
mice
vaccin
month
apart
differ
combin
low
dose
vpmous
induc
measur
nva
shown
fig
primeboost
vaccin
induc
appar
low
immun
respons
geomean
ceaspecif
pbmc
respond
mice
compar
regimen
geomean
respect
respond
taken
togeth
data
show
similar
potenc
compar
elicit
ceaspecif
immun
respons
impact
preexist
immun
test
mice
previous
expos
high
dose
wild
type
vp
one
month
later
anim
develop
high
titer
nva
titer
treat
one
inject
express
vector
see
scheme
fig
ceaspecif
cell
immun
respons
unaffect
anim
vaccin
see
fig
refer
complet
abolish
mice
receiv
treatment
effect
immun
recal
phase
also
evalu
tg
mice
preinject
vp
wild
type
immun
either
vp
averag
titer
group
shown
two
week
later
immun
respons
cea
measur
intracellular
stain
b
preexposur
wt
impair
vaccin
potenc
group
ceatg
mice
receiv
weekli
dnaep
left
untreat
mock
two
week
anim
inject
vp
either
two
vector
immun
respons
cea
measur
day
later
intracellular
stain
c
kinet
immun
respons
treat
mice
bled
indic
time
point
pbmc
analyz
intracellular
stain
mice
ceaspecif
respons
consid
respond
follow
previou
treatment
dnaep
ceatg
mice
preexist
immun
receiv
weekli
dnaep
treatment
week
later
inject
ad
vector
immun
respons
measur
thereaft
shown
fig
antibodi
complet
blunt
prime
boost
capabl
regimen
contain
contrast
poor
reduct
observ
mice
receiv
vector
similarli
durat
respons
treat
anim
affect
preexist
immun
fig
data
indic
antibodi
unabl
impair
immun
potenc
homolog
heterolog
vaccin
set
extend
observ
anoth
taamous
model
util
balbneut
mice
one
suitabl
model
vaccin
evalu
sinc
femal
mice
develop
autochthon
spontan
synchron
breast
cancer
mammari
gland
antitumor
respons
highli
correl
immun
respons
rat
neu
two
weekli
inject
neuecdtm
week
suffici
induc
strong
neuspecif
tcell
respons
mean
measur
intracellular
stain
week
respons
persist
signific
level
least
anoth
week
week
see
fig
time
point
least
mice
respond
vaccin
two
similarli
space
weekli
inject
neuecdtm
induc
slightli
lower
tcell
respons
neuecdtm
inject
case
mice
respond
first
time
point
persist
second
pbmc
collect
salin
treat
mice
control
show
produc
cell
data
shown
determin
whether
neutral
antibodi
crossreact
mous
model
group
mice
immun
previous
describ
two
inject
either
open
circl
indic
respons
individu
mice
fill
circl
denot
group
mean
mous
tcell
reactiv
least
consid
respond
student
ttest
week
p
vs
alon
alon
b
antibodi
titer
antirat
titer
determin
describ
materi
method
least
mice
includ
group
open
circl
indic
respons
individu
mice
fill
circl
denot
group
mean
student
ttest
p
vs
alon
alon
c
antitumor
effect
mice
immun
describ
text
tumor
develop
follow
week
onward
least
mice
includ
group
percentag
tumorfre
mice
shown
group
symbol
shown
graph
legend
logrank
test
vs
p
neuecdtm
neuecdtm
two
week
prior
vaccin
mice
inject
particl
wild
type
induc
neutral
antibodi
follow
administr
vaccin
tcell
respons
analyz
mice
receiv
wild
type
prior
neuecdtm
show
detect
neuspecif
cell
respons
intracellular
stain
fig
mean
respons
drop
undetect
suggest
vector
neutral
preexist
humor
respons
contrast
signific
drop
immunogen
observ
neuecdtm
immun
mice
mice
respond
time
point
similar
result
obtain
antibodi
respons
rat
also
strongli
affect
preexposur
wt
final
assess
vaccin
could
confer
therapeut
anticanc
effect
tumor
palpat
week
onward
two
inject
result
mice
remain
tumor
free
week
fig
similarli
data
obtain
two
inject
show
mice
tumor
free
week
control
mice
develop
tumor
week
group
receiv
preimmun
wt
also
evalu
presenc
neutral
antibodi
drastic
reduc
efficaci
neuecdtm
week
none
mice
tumor
free
hand
preexist
immun
impact
antitumor
effect
neuecdtm
immun
mice
tumor
free
without
preexposur
data
confirm
humor
immun
crossreact
therefor
new
vector
effect
substitut
mice
cancer
immun
therapi
translat
clinic
strictli
depend
effici
vaccin
technolog
deliveri
system
evalu
appropri
preclin
model
ceatg
mice
express
cea
tissu
distribut
similar
human
provid
particularli
relev
model
critic
verifi
potenti
efficaci
human
ceabas
vaccin
similarli
balbneut
mice
allow
assess
activ
cancer
immunotherapi
overexpress
activ
form
rat
oncogen
control
mous
mammari
tumor
viru
promot
lead
progress
develop
invas
mammari
adenocarcinoma
ten
mammari
gland
shown
dnaep
technolog
particularli
carrier
along
codon
usag
optim
antigen
engin
lead
breakag
immun
toler
hamper
cancer
progress
model
except
immunogen
replicationdefect
vector
probabl
due
number
properti
high
level
transgen
express
driven
vector
potent
cytomegaloviru
promot
ii
activ
innat
immun
system
iii
transduct
immatur
dendrit
cell
drive
matur
antigenpres
cell
iv
suffici
long
durat
antigen
present
due
lack
apoptosi
induct
transduc
cell
howev
preexist
antiadenoviru
immun
particular
neutral
antibodi
reduc
cell
uptak
adenovir
vector
significantli
dampen
vaccin
respons
repres
major
limit
success
use
common
serotyp
adenoviru
circumv
impair
vaccin
efficaci
preexist
neutral
antibodi
develop
vaccin
vector
base
ad
isol
chimpanze
one
close
sequenc
homolog
viru
thu
belong
subgroup
c
adenoviridea
colloca
et
al
prepar
studi
show
similar
infect
potenc
vitro
vivo
fig
primari
receptor
respons
attach
ad
serotyp
except
group
b
use
car
recent
studi
shown
ad
also
use
receptor
major
histocompat
complex
mhci
heparin
sulfat
glycosaminoglycan
gene
transfer
efficaci
mediat
investig
larg
panel
human
primari
cell
differ
tissu
origin
found
similar
colloca
et
al
prepar
suggest
vector
util
entri
mechan
least
vitro
cultur
cell
howev
express
cea
appar
lower
im
inject
mice
fig
suggest
vector
may
differ
properti
andor
tropism
transduc
mous
tissu
compar
importantli
abl
break
toler
ceatg
mice
induc
potent
antigenspecif
respons
kinet
compar
fig
b
thu
indic
vector
could
infect
cell
instrument
antigen
express
induct
immun
respons
via
direct
indirect
present
antigen
neu
ecdtm
show
similar
immunogen
properti
balbneut
mice
fig
b
vector
also
show
good
efficaci
boost
elicit
immun
respons
heterolog
type
vaccin
fig
featur
import
sinc
regimen
consist
rare
serotyp
ad
vector
combin
recent
proven
abl
elicit
augment
magnitud
breadth
polyfunction
cellular
immun
respons
superior
protect
efficaci
compar
homolog
regimen
vector
develop
overcom
preexist
serotypespecif
neutral
antibodi
shown
interfer
efficaci
homolog
vaccin
carrier
limit
could
part
circumv
increas
vaccin
dose
may
result
sever
vectormedi
toxic
inde
crossneutr
immun
respons
occur
anim
high
titer
preexist
immun
fig
equal
ad
boost
effect
consequ
dnaep
prime
impair
fig
c
final
show
neu
ecdtm
antitumor
effect
compar
correspond
vector
import
vaccin
efficaci
blunt
presenc
neutral
antibodi
fig
associ
measur
immun
respons
recent
chimpanze
ad
vector
proven
particularli
effect
tool
vaccin
varieti
viral
antigen
diseas
influenza
caus
strain
human
immunodefici
viru
type
nhp
rabi
viru
sever
acut
respiratori
syndrom
mediat
sarscoronaviru
note
model
organ
recogn
antigen
exogen
protein
consequ
elicit
immun
respons
gener
strong
effect
target
pathogen
hand
choos
appropri
preclin
model
taa
recogn
selfprotein
imper
better
predict
possibl
outcom
cancer
vaccin
human
patient
report
first
time
novel
chimp
ad
vector
employ
potent
cancer
vaccin
tool
may
prove
particularli
use
vaccin
vector
popul
develop
world
high
level
preexist
immun
addit
vector
could
util
togeth
common
vector
dnaep
heterolog
primeboost
regimen
